Compass Inc. Class A Common Stock vs Davita Inc — how do they compare? Compass Inc. Class A Common Stock trades at $9.39 (market cap $7.31B), while Davita Inc trades at $179.05 (market cap $11.29B). The key difference: Davita Inc is the larger of the two by market cap, and Davita Inc is trading nearer its 52-week high, Compass Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Compass Inc. Class A Common Stock for 1 Days and Davita Inc for 114 Days on average.
| COMP | DVA | |
|---|---|---|
Market Cap | $7.31B | $11.29B |
Volume | 15,861,865 | 582,204 |
Sector | Real Estate | Health |
52-Week High | $13.58 | $240.96 |
52-Week Low | $6.68 | $103.87 |
Typical Hold Time | 1 Days | 114 Days |
Enterprise Value | $10.72B | $24.01B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
DaVita (DVA) trades at $179.25, up 1.4% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows mixed technical signals with bearish moving averages but neutral oscillators, trading near resistance at $179. Fundamentally, revenue growth continues with 2025 revenue reaching $13.64B, though net margins compressed to 5.47% from 7.3% in 2024. Recent partnership expansion with Humana for value-based kidney care represents significant growth opportunity.
Outlook remains positive with analyst consensus target of $235.67 implying 31% upside, though elevated debt levels and regulatory risks require monitoring. The company benefits from demographic tailwinds in kidney care services and strong institutional support, including Berkshire Hathaway's 45% stake, providing stability amid market volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Compass is a technology-enabled residential real estate company. Its platform provides agents with tools for customer relationships, marketing, client service, and transactions, alongside brokerage, title, escrow, and mortgage services.
Read more on COMP →DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →